acalabrutinib-obinutuzumab in cll: 3-year follow-up
Published 5 years ago • 202 plays • Length 1:11Download video MP4
Download video MP3
Similar videos
-
6:34
3-year follow-up of obinutuzumab, ibrutinib and venetoclax for cll
-
1:59
acalabrutinib, venetoclax and obinutuzumab upfront for cll
-
1:15
the current role of acalabrutinib in the treatment of cll
-
1:50
insights into the majic study: acalabrutinib venetoclax vs venetoclax obinutuzumab in cll
-
2:39
the safety and efficacy of ibrutinib for the treatment of cll
-
2:57
selecting between ibrutinib, acalabrutinib and zanubrutinib in the frontline setting in cll
-
13:20
a phase 3 study of biosimilar bi 695501 versus adalimumab in patients with crohn’s disease - vjbm
-
2:37
resistance to acalabrutinib in cll is mediated by btk mutations
-
1:46
novel agent combinations for cll: ibrutinib, venetoclax, obinutuzumab and zanubrutinib
-
1:36
cll2-give trial: ibrutinib, venetoclax and obinutuzumab in patients with tp53-mutated cll
-
4:58
overview of the toxicities associated with bispecific agents in multiple myeloma
-
1:36
evaluating acalabrutinib in cll treatment
-
2:58
results of a phase ib study of ibrutinib obinutuzumab in r/r cll
-
1:05
final analysis of the alpine trial: zanubrutinib vs ibrutinib in r/r cll
-
4:31
sequence of administration of ibrutinib with obinutuzumab in r/r cll patients
-
1:02
a phase ii single-arm study of obinutuzumab plus ibrutinib as frontline treatment for fl and mzl
-
2:11
atezolizumab with venetoclax and obinutuzumab in patients with cll
-
1:44
the impact of acalabrutinib treatment by line of therapy in patients with cll
-
2:29
real-world comparison of ttnt with ibrutinib or acalabrutinib in cll
-
2:18
the combination of ibrutinib and obinutuzumab in cll
-
3:00
five-year follow-up of the captivate trial: ibrutinib retreatment in patients with cll
-
2:00
obinutuzumab, ibrutinib, and venetoclax in high-risk cll: the cll2-give and cll13 trials